8-K Announcements
6Material company update
Jan 7, 2026·SEC
Material company update
Nov 14, 2025·SEC
Material company update
Nov 6, 2025·SEC
Cidara Therapeutics, Inc.(CDTX)Earnings, Financials & Key Ratios
CDTX•NASDAQ
$221.38
$6.96B mkt cap·Price updated Apr 24, 2026
AboutCidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.Show more
- Revenue$1M-94.5%
- EBITDA-$176M-552.6%
- Net Income-$170M-640.6%
- EPS (Diluted)-26.75-409.5%
- Gross Margin100%+272.7%
- EBITDA Margin-13793.65%-11817.7%
- Operating Margin-13811.92%-11784.1%
- Net Margin-13319.76%-13424.2%
- ROE-218.99%
- Debt/Equity0.02
CDTX Key Insights
Cidara Therapeutics, Inc. (CDTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 42.9% over 5 years
- ✗Shares diluted 45.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CDTX Price & Volume
Cidara Therapeutics, Inc. (CDTX) stock price & volume — 10-year historical chart
Loading chart...
CDTX Growth Metrics
Cidara Therapeutics, Inc. (CDTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-42.85%
3 Years-70.48%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM53.79%
Return on Capital
10 Years-202.8%
5 Years-335.09%
3 Years-434.89%
Last Year-213.65%
CDTX Recent Earnings
Cidara Therapeutics, Inc. (CDTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (57%)
Q4 2025Latest
Nov 6, 2025EPS
$1.43
Est $1.34
-6.7%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$1.65
Est $1.87
+11.8%
Revenue
—
Q2 2025
May 8, 2025EPS
$1.66
Est $5.45
+69.5%
Revenue
—
Q2 2025
Mar 6, 2025EPS
$5.38
Est $5.28
-1.9%
Revenue
—
Est $240,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $1.43vs $1.34-6.7% | — |
| Q3 2025 | Aug 7, 2025 | $1.65vs $1.87+11.8% | — |
| Q2 2025 | May 8, 2025 | $1.66vs $5.45+69.5% | — |
| Q2 2025 | Mar 6, 2025 | $5.38vs $5.28-1.9% | —vs $240,000 |
Based on last 12 quarters of dataView full earnings history →
CDTX Peer Comparison
Cidara Therapeutics, Inc. (CDTX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 AGIO | 1.62B | 27.21 | -3.82 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 ENTA | 420.2M | 14.48 | -3.77 | -3.42% | -106.8% | -56.51% | 3.11 | |
 MGNX | 199.45M | 3.15 | -2.67 | 0.78% | -49.91% | -120.2% | 0.66 | |
 AMPH | 1.04B | 23.39 | 11.52 | -1.65% | 13.63% | 12.76% | 11.64% | 0.83 |
 CMPX | 347.73M | 1.95 | -4.64 | -100% | -43.61% | 0.05 | ||
 ARDX | 1.75B | 7.13 | -27.42 | 22.09% | -13.58% | -38.11% | 1.27 |
Compare CDTX vs Peers
Cidara Therapeutics, Inc. (CDTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CDTX Income Statement
Cidara Therapeutics, Inc. (CDTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 20.91M | 12.07M | 49.57M | 64.45M | 23.28M | 1.27M | 0 |
| Revenue Growth % | - | - | - | - | -42.3% | 310.81% | 30.01% | -63.87% | -94.52% | -100% |
| Cost of Goods Sold | 732K | 667K | 523K | 46.4M | 0 | 73.09M | 0 | 36.76M | 0 | 45M |
| COGS % of Revenue | - | - | - | 221.86% | - | 147.44% | - | 157.9% | - | - |
| Gross Profit | -732K▲ 0% | -667K▲ 8.9% | -523K▲ 21.6% | -25.49M▼ 4773.0% | 12.07M▲ 147.3% | -23.52M▼ 294.9% | 64.45M▲ 374.1% | -13.48M▼ 120.9% | 1.27M▲ 109.5% | -45M▲ 0% |
| Gross Margin % | - | - | - | -121.86% | 100% | -47.44% | 100% | -57.9% | 100% | - |
| Gross Profit Growth % | -58.79% | 8.88% | 21.59% | -4773.04% | 147.35% | -294.87% | 374.07% | -120.92% | 109.46% | - |
| Operating Expenses | 48.44M | 55.72M | 63.28M | 62.64M | 83.92M | 18.74M | 97.95M | 13.58M | 177.38M | 150.46M |
| OpEx % of Revenue | - | - | - | 299.49% | 695.42% | 37.8% | 151.98% | 58.33% | 13911.92% | - |
| Selling, General & Admin | 12.74M | 12.9M | 14.14M | 16.24M | 15.9M | 18.74M | 20.55M | 13.58M | 20.61M | 28.09M |
| SG&A % of Revenue | - | - | - | 77.64% | 131.76% | 37.8% | 31.88% | 58.33% | 1616.86% | - |
| Research & Development | 35.7M | 42.82M | 49.14M | 46.4M | 68.02M | 73.09M | 77.41M | 36.76M | 156.76M | 131.82M |
| R&D % of Revenue | - | - | - | 221.86% | 563.66% | 147.44% | 120.1% | 157.9% | 12295.06% | - |
| Other Operating Expenses | 0 | 0 | -211K | 0 | 0 | -73.09M | 0 | -36.76M | 0 | -2M |
| Operating Income | -48.44M▲ 0% | -55.72M▼ 15.0% | -63.28M▼ 13.6% | -41.72M▲ 34.1% | -71.85M▼ 72.2% | -42.26M▲ 41.2% | -33.5M▲ 20.7% | -27.06M▲ 19.2% | -176.1M▼ 550.8% | -195.46M▲ 0% |
| Operating Margin % | - | - | - | -199.49% | -595.42% | -85.24% | -51.98% | -116.22% | -13811.92% | - |
| Operating Income Growth % | -49.9% | -15.04% | -13.57% | 34.07% | -72.2% | 41.19% | 20.71% | 19.23% | -550.78% | - |
| EBITDA | -47.7M | -55.05M | -62.76M | -41.4M | -70.8M | -42.07M | -33.36M | -26.95M | -175.87M | -195.3M |
| EBITDA Margin % | - | - | - | -197.92% | -586.72% | -84.86% | -51.76% | -115.74% | -13793.65% | - |
| EBITDA Growth % | -49.77% | -15.41% | -14% | 34.04% | -71.03% | 40.58% | 20.7% | 19.22% | -552.62% | -52.82% |
| D&A (Non-Cash Add-back) | 732K | 667K | 523K | 328K | 1.05M | 189K | 143K | 112K | 233K | 163K |
| EBIT | -48.44M | -55.72M | -63.28M | -41.72M | -71.85M | -42.26M | -33.5M | -27.06M | -176.1M | -190.07M |
| Net Interest Income | 0 | -7K | 0 | 221K | -262K | 0 | 191K | 2M | 5.81M | 5.38M |
| Interest Income | 0 | 0 | 0 | 221K | 0 | 0 | 191K | 2M | 5.81M | 5.38M |
| Interest Expense | 271K | 7K | 629K | 0 | 262K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 271K | -7K | 4.27M | 632K | -262K | -212K | 191K | 2M | 5.81M | 10.66M |
| Pretax Income | -48.16M▲ 0% | -55.73M▼ 15.7% | -59.02M▼ 5.9% | -41.09M▲ 30.4% | -72.11M▼ 75.5% | -42.47M▲ 41.1% | -33.31M▲ 21.6% | -25.07M▲ 24.8% | -170.29M▼ 579.4% | -184.8M▲ 0% |
| Pretax Margin % | - | - | - | -196.47% | -597.59% | -85.67% | -51.69% | -107.65% | -13356.16% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 272K | 15K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -0.82% | -0.06% | 0% | 0% |
| Net Income | -48.16M▲ 0% | -55.73M▼ 15.7% | -59.02M▼ 5.9% | -41.09M▲ 30.4% | -72.11M▼ 75.5% | -42.47M▲ 41.1% | -33.58M▲ 20.9% | -22.93M▲ 31.7% | -169.83M▼ 640.6% | -184.74M▲ 0% |
| Net Margin % | - | - | - | -196.47% | -597.59% | -85.67% | -52.11% | -98.49% | -13319.76% | - |
| Net Income Growth % | -49.61% | -15.7% | -5.9% | 30.37% | -75.49% | 41.11% | 20.92% | 31.72% | -640.6% | -50.03% |
| Net Income (Continuing) | -48.16M | -55.73M | -59.02M | -41.09M | -72.11M | -42.47M | -33.58M | -25.08M | -170.29M | -184.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.15M | 464K | 62K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -66.49▲ 0% | -63.69▲ 4.2% | -45.62▲ 28.4% | -26.78▲ 41.3% | -36.03▼ 34.5% | -16.19▲ 55.1% | -9.61▲ 40.6% | -5.25▲ 45.4% | -26.75▼ 409.5% | -11.88▲ 0% |
| EPS Growth % | -42.19% | 4.21% | 28.37% | 41.3% | -34.54% | 55.07% | 40.64% | 45.37% | -409.52% | 53.79% |
| EPS (Basic) | -66.49 | -63.69 | -45.62 | -26.78 | -36.03 | -16.20 | -9.61 | -5.25 | -26.75 | - |
| Diluted Shares Outstanding | 724.45K | 875.04K | 1.29M | 1.5M | 2.08M | 2.62M | 3.49M | 4.37M | 6.35M | 15.55M |
| Basic Shares Outstanding | 724.45K | 875.04K | 1.29M | 1.5M | 2.08M | 2.62M | 3.49M | 4.37M | 6.35M | 15.55M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CDTX Balance Sheet
Cidara Therapeutics, Inc. (CDTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 105.4M | 77.67M | 77.13M | 65.81M | 57.19M | 71.7M | 45.09M | 60.85M | 210.74M | 442.82M |
| Cash & Short-Term Investments | 104.62M | 75.31M | 74.56M | 50.27M | 35.91M | 62.27M | 32.73M | 35.78M | 189.82M | 293.65M |
| Cash Only | 104.62M | 75.31M | 74.56M | 50.27M | 35.91M | 62.27M | 32.73M | 35.78M | 189.82M | 293.65M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 321K | 0 | 10K | 11.18M | 5.36M | 5.83M | 16.25M | 1.69M | 1.86M |
| Days Sales Outstanding | - | - | - | 0.17 | 338.02 | 39.44 | 33.04 | 254.68 | 484.95 | - |
| Inventory | 0 | -321K | 0 | 0 | 0 | -2.59M | 0 | 6.1M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 60.53 | - | - |
| Other Current Assets | 779K | 0 | 2.57M | 10M | 7.04M | 2.59M | 0 | 2.73M | 19.22M | 147.31M |
| Total Non-Current Assets | 1.56M | 1.36M | 1.98M | 3.16M | 3.23M | 3.63M | 2.39M | 6.17M | 4.06M | 75.83M |
| Property, Plant & Equipment | 1.37M | 1.04M | 712K | 2.06M | 1.21M | 2.54M | 1.32M | 5.13M | 3.96M | 2.09M |
| Fixed Asset Turnover | - | - | - | 10.15x | 9.97x | 19.49x | 48.79x | 4.54x | 0.32x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50.16M |
| Other Non-Current Assets | 190K | 321K | 1.27M | 1.1M | 2.02M | 533K | 1.07M | 1.05M | 96K | 23.87M |
| Total Assets | 106.96M▲ 0% | 79.03M▼ 26.1% | 79.11M▲ 0.1% | 68.98M▼ 12.8% | 60.42M▼ 12.4% | 75.33M▲ 24.7% | 47.49M▼ 37.0% | 67.03M▲ 41.2% | 214.8M▲ 220.4% | 518.65M▲ 0% |
| Asset Turnover | - | - | - | 0.30x | 0.20x | 0.66x | 1.36x | 0.35x | 0.01x | 0.00x |
| Asset Growth % | -2.74% | -26.11% | 0.1% | -12.81% | -12.4% | 24.66% | -36.96% | 41.15% | 220.45% | 911.87% |
| Total Current Liabilities | 8.91M | 12.09M | 19.89M | 30.2M | 38.56M | 34.02M | 41.4M | 67.42M | 49.55M | 95.84M |
| Accounts Payable | 2.91M | 2.59M | 2.85M | 1.89M | 4.57M | 1.3M | 1.45M | 3.77M | 3.61M | 4.35M |
| Days Payables Outstanding | 1.45K | 1.42K | 1.99K | 14.84 | - | 6.5 | - | 37.45 | - | 30.54 |
| Short-Term Debt | 0 | 2.67M | 9.93M | 9.96M | 7.02M | 2.59M | 0 | 0 | 0 | 1.56M |
| Deferred Revenue (Current) | 0 | 0 | 6.71M | 9.8M | 13.87M | 13.92M | 14.61M | 25.09M | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 4.29M | 3.66M | 4.21M | 10.2M | 4.92M | 32.22M | 44.3M | 89.93M |
| Current Ratio | 11.83x | 6.43x | 3.88x | 2.18x | 1.48x | 2.11x | 1.09x | 0.90x | 4.25x | 4.25x |
| Quick Ratio | 11.83x | 6.45x | 3.88x | 2.18x | 1.48x | 2.18x | 1.09x | 0.81x | 4.25x | 4.25x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 277.77 | - | - |
| Total Non-Current Liabilities | 9.87M | 7.21M | 81K | 942K | 11.14M | 19.73M | 20.52M | 7.82M | 1.93M | 424K |
| Long-Term Debt | 9.79M | 7.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 424K |
| Capital Lease Obligations | 0 | 0 | 0 | 942K | 0 | 1.32M | 0 | 3.58M | 1.93M | 4.01M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 80K | 0 | 81K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 18.78M | 19.29M | 19.97M | 31.14M | 49.71M | 53.75M | 61.92M | 75.24M | 51.49M | 96.26M |
| Total Debt | 9.79M | 9.87M | 9.93M | 11.72M | 7.96M | 5.06M | 1.21M | 4.88M | 3.58M | 1.98M |
| Net Debt | -94.83M | -65.44M | -64.63M | -38.54M | -27.95M | -57.21M | -31.52M | -30.9M | -186.25M | -291.67M |
| Debt / Equity | 0.11x | 0.17x | 0.17x | 0.31x | 0.74x | 0.23x | - | - | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.49x |
| Interest Coverage | -178.73x | -7960.14x | -100.61x | - | -274.23x | - | - | - | - | - |
| Total Equity | 88.18M▲ 0% | 59.74M▼ 32.2% | 59.14M▼ 1.0% | 37.84M▼ 36.0% | 10.71M▼ 71.7% | 21.57M▲ 101.3% | -14.44M▼ 166.9% | -8.21M▲ 43.1% | 163.31M▲ 2089.1% | 422.39M▲ 0% |
| Equity Growth % | -15.14% | -32.25% | -1.01% | -36.02% | -71.68% | 101.33% | -166.93% | 43.14% | 2089.14% | 3534.05% |
| Book Value per Share | 121.72 | 68.28 | 45.72 | 25.28 | 5.16 | 8.23 | -4.13 | -1.88 | 25.72 | 27.17 |
| Total Shareholders' Equity | 88.18M | 59.74M | 59.14M | 37.84M | 10.71M | 21.57M | -14.44M | -8.21M | 163.31M | 422.39M |
| Common Stock | 2K | 2K | 3K | 3K | 4K | 7K | 7K | 9K | 1K | 3K |
| Retained Earnings | -93.66M | -149.39M | -218.74M | -259.83M | -334.7M | -377.17M | -418.5M | -441.43M | -611.26M | -743.69M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | -8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -107K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CDTX Cash Flow Statement
Cidara Therapeutics, Inc. (CDTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -39.77M | -49.91M | -56.7M | -28.53M | -54.41M | -25.23M | -28.47M | -22.43M | -176.53M | -176.53M |
| Operating CF Margin % | - | - | - | -136.42% | -450.91% | -50.9% | -44.18% | -96.34% | -13845.73% | - |
| Operating CF Growth % | -53.21% | -25.49% | -13.62% | 49.68% | -90.7% | 53.63% | -12.84% | 21.22% | -686.97% | -311.73% |
| Net Income | -48.16M | -55.73M | -59.02M | -41.09M | -72.11M | -42.47M | -33.58M | -22.93M | -169.83M | -184.74M |
| Depreciation & Amortization | 732K | 667K | 523K | 375K | 229K | -1.23M | 143K | 118K | 233K | 163K |
| Stock-Based Compensation | 4.34M | 5.71M | 5.71M | 5.07M | 4.09M | 4.01M | 3.53M | 3.06M | 3.91M | 9.53M |
| Deferred Taxes | -176K | -33K | -3.61M | -411K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 14K | 50K | 86K | 36K | 21K | 15K | 982K | 1.24M | 3.09M | -8.24M |
| Working Capital Changes | 3.48M | -579K | -399K | 7.49M | 13.36M | 14.44M | 454K | -3.92M | -13.93M | 50.35M |
| Change in Receivables | 0 | 0 | 321K | -10K | -11.16M | 5.82M | -477K | -10.41M | 14.28M | -162K |
| Change in Inventory | 0 | 0 | 0 | 10K | -6.59M | 1.09M | 0 | -6.1M | 6.1M | 0 |
| Change in Payables | 1.91M | 642K | -59K | -784K | 6.59M | -1.09M | -2.37M | 8.89M | -1M | 64.17M |
| Cash from Investing | 25.48M | 4.47M | 14.3M | -35K | -186K | -41K | -118K | -505K | -129K | -176.28M |
| Capital Expenditures | -401K | -306K | -177K | -35K | -186K | -41K | -118K | -505K | -129K | 0 |
| CapEx % of Revenue | - | - | - | 0.17% | 1.54% | 0.08% | 0.18% | 2.17% | 10.12% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 25.88M | 4.78M | 14.48M | 0 | 0 | 0 | 0 | 0 | 0 | -176.47M |
| Cash from Financing | 37.09M | 20.88M | 56.15M | 14.27M | 37.28M | 44.6M | -951K | 25.98M | 337.06M | 481.83M |
| Debt Issued (Net) | 9.95M | 0 | 0 | 0 | -2.96M | -4.44M | -2.59M | 0 | -276K | -126K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.13M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 525K | 228K | 49.71M | -24K | 14K | 6K | -720K | 21K | 7K | 1.56M |
| Net Change in Cash | 22.8M▲ 0% | -24.55M▼ 207.7% | 13.75M▲ 156.0% | -14.29M▼ 204.0% | -17.32M▼ 21.2% | 19.32M▲ 211.6% | -29.54M▼ 252.9% | 3.05M▲ 110.3% | 160.4M▲ 5164.2% | 172.6M▲ 0% |
| Free Cash Flow | -40.17M▲ 0% | -50.22M▼ 25.0% | -56.88M▼ 13.3% | -28.57M▲ 49.8% | -54.6M▼ 91.1% | -25.27M▲ 53.7% | -28.59M▼ 13.1% | -22.94M▲ 19.8% | -176.66M▼ 670.2% | -132.94M▲ 0% |
| FCF Margin % | - | - | - | -136.59% | -452.45% | -50.98% | -44.36% | -98.51% | -13855.84% | - |
| FCF Growth % | -48.08% | -25% | -13.28% | 49.78% | -91.12% | 53.71% | -13.13% | 19.78% | -670.21% | 16.99% |
| FCF per Share | -55.45 | -57.39 | -43.97 | -19.09 | -26.28 | -9.64 | -8.19 | -5.25 | -27.82 | -27.82 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.90x | 0.96x | 0.69x | 0.75x | 0.59x | 0.85x | 0.98x | 1.04x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 40K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 797K | 95K | 0 |
CDTX Key Ratios
Cidara Therapeutics, Inc. (CDTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -50.15% | -75.35% | -99.28% | -84.75% | -297.06% | -263.05% | -941.39% | - | -218.99% | -43.74% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | -762.39% |
| Gross Margin | - | - | - | -121.86% | 100% | -47.44% | 100% | -57.9% | 100% | - |
| Net Margin | - | - | - | -196.47% | -597.59% | -85.67% | -52.11% | -98.49% | -13319.76% | - |
| Debt / Equity | 0.11x | 0.17x | 0.17x | 0.31x | 0.74x | 0.23x | - | - | 0.02x | 0.02x |
| Interest Coverage | -178.73x | -7960.14x | -100.61x | - | -274.23x | - | - | - | - | - |
| FCF Conversion | 0.83x | 0.90x | 0.96x | 0.69x | 0.75x | 0.59x | 0.85x | 0.98x | 1.04x | 0.72x |
| Revenue Growth | - | - | - | - | -42.3% | 310.81% | 30.01% | -63.87% | -94.52% | -100% |
CDTX SEC Filings & Documents
Cidara Therapeutics, Inc. (CDTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CDTX Frequently Asked Questions
Cidara Therapeutics, Inc. (CDTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cidara Therapeutics, Inc. (CDTX) reported $1.3M in revenue for fiscal year 2024.
Cidara Therapeutics, Inc. (CDTX) saw revenue decline by 94.5% over the past year.
Cidara Therapeutics, Inc. (CDTX) reported a net loss of $184.7M for fiscal year 2024.
Dividend & Returns
Cidara Therapeutics, Inc. (CDTX) has a return on equity (ROE) of -219.0%. Negative ROE indicates the company is unprofitable.
Cidara Therapeutics, Inc. (CDTX) had negative free cash flow of $132.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More CDTX
Cidara Therapeutics, Inc. (CDTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates